Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: The E2F4 prognostic signature predicts pathological response to neoadjuvant chemotherapy in breast cancer patients

Fig. 4

Classification performance after including clinicopathological features into pCR classification models. Comparison of AUCs between combinations of the E2F4 signature, Oncotype DX, MammaPrint, and clinicopathological features in a ER-positive patients and b ER-negative patients. Error bars indicate standard deviation calculated by performing 10-fold cross-validation 100 times

Back to article page